Endo Pharmaceuticals Holdings News

Shares of Endo Pharmaceuticals traded up 0.09% during mid-day trading on Tuesday, hitting $33.74. Endo Pharmaceuticals has a 52 week low of $25.01 and a 52 week high of $36.82. The stock's 50-day moving average is currently $32.58. The company's market cap is $3.787 billion.

The company announced that the FDA has denied its Citizen Petition that would've blocked generic versions of its crush resistant pain killer OPANA.

Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- Affymax, Inc.

Malvern-based Endo Health Solutions Inc. dealt Monday with the fallout from an adverse decision Friday by the Food and Drug Administration, which rejected Endo's complicated request to deny approval to generic competitors of Endo's opioid painkiller, Opana ER.

This morning, UBS reduced its price target on shares of Endo Health Solutions to $39 per share following an unfavorable FDA ruling last week.

FDA Rejects Endo Health Solutions Inc. Petition to Protect Its Painkiller Franchise Staying up-to-date has never been simpler.

Shares of Endo Pharmaceuticals opened at 33.19 on Monday. Endo Pharmaceuticals has a one year low of $25.01 and a one year high of $36.82. The stock's 50-day moving average is currently $32.58. The company's market cap is $3.725 billion.

The firm currently has a "buy" rating on the stock. ENDP has been the subject of a number of other recent research reports.

The firm currently has an "underperform" rating on the stock. Shares of Endo Pharmaceuticals traded down 5.28% during mid-day trading on Wednesday, hitting $34.97. Endo Pharmaceuticals has a 52 week low of $25.01 and a 52 week high of $36.82. The stock's 50-day moving average is currently $32.58. The company's market cap is $3.881 billion.

Shares of Endo Pharmaceuticals traded down 5.28% during mid-day trading on Wednesday, hitting $34.97. Endo Pharmaceuticals has a 52 week low of $25.01 and a 52 week high of $36.82. The stock's 50-day moving average is currently $32.58. The company's market cap is $3.881 billion.

MALVERN, Pa., May 10, 2013 /PRNewswire/ -- Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has denied a Citizen Petition filed by its subsidiary, Endo Pharmaceuticals Inc.

Endo Health Solutions Inc. lost an effort to stop U.S. sales of generic versions of its extended-release painkiller that don't have tamper-resistant qualities.

's stock had its "buy" rating restated by equities researchers at Jefferies Group in a report issued on Thursday, Analyst Ratings.Net reports.

's stock had its "neutral" rating reaffirmed by Zacks in a research note issued on Thursday, Analyst Ratings.Net reports.

In a report published Thursday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions , and raised the price target from $44.00 to $47.00. In the report, Davis noted, "Light 1Q revenues were attributable to Lidoderm since we misgauged the normal seasonal dip in ASP.

Several other analysts have also recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Endo Pharmaceuticals from $28.00 to $29.00 in a research note to investors on Wednesday.

Results from Large Randomized Trial Support Use of Innovative 180 Watt Laser Therapy as a Viable Treatment Option for More Than 110 Million Men Worldwide with Enlarged Prostate Results from Large Randomized Trial Support Use of Innovative 180 Watt Laser Therapy as a Viable Treatment Option for More Than 110 Million Men Worldwide with Enlarged ... (more)

A number of other analysts have also recently weighed in on ENDP. Analysts at TheStreet reiterated a "hold" rating on shares of Endo Pharmaceuticals in a research note to investors on Tuesday, April 23rd.

StockCall.com Provides Stock Research on Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Pharmaceuticals Holdings Inc., and Allergan Inc.

American Medical Systems and other subsidiaries of Endo Pharmaceuticals, Inc. were removed earlier this month as defendants in the federal consolidations of transvaginal mesh lawsuits , according to court documents reviewed by the Rottenstein Law Group, a transvaginal mesh law firm.